TXG · NASDAQ · STOCK
10x Genomics, Inc.
$58.48
52W $11.16 – $60.69
53/100
$7.42B
-99.1
2.04
Is TXG Bullish or Bearish?
Mixed.
Innellis AI committee rates 10x Genomics, Inc. (TXG) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +6.60 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -13.40 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -4.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- ROE of only -9.3% -- cheap may mean cheap for a reason — Value
- Revenue declining -4.3% YoY -- this is not a growth story right now — Growth
- RSI at 79 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 94 -- overbought on the larger timeframe too — Technical
- Bollinger bandwidth of 34.3% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 90%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -9.3% -- cheap may mean cheap for a reason
Growth Analyst
bearish
15
/ 100 · Low confidence
Growth story is weak, decelerating, or inconsistent
− Revenue declining -4.3% YoY -- this is not a growth story right now
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
− Bollinger bandwidth of 34.3% signals elevated volatility
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
79.3
Overbought
MACD Histogram
0.689
Bullish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
1.14
Above Upper Band
Price vs Moving Averages
EMA 9
$51.72
Above
EMA 21
$47.84
Above
EMA 50
$41.27
Above
EMA 200
$27.59
Above
Fundamental Analysis
Valuation
67
Profitability
25
Financial Health
100
Cash Flow
70
Valuation
P/E Ratio
-99.1×
P/B Ratio
9.21×
PEG Ratio
0.22
Dividend Yield
0.00%
52W High
$60.69
52W Low
$11.16
Quality & Growth
ROE
-546.8%
ROA
-418.1%
Gross Margin
7003.1%
Operating Margin
-1432.7%
Revenue Growth YoY
—
Debt / Equity
0.10
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -99.1 (inexpensive relative to a 15-40x range); Price-to-book of 9.2x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -5.5%; Return on assets of -4.2%; Net margin of -12.2%; Gross margin of 70.0%; Current ratio of 5.69 (healthy short-term liquidity); Debt-to-equity of 0.10; Free cash flow per share is positive (0.93); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full TXG Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →